NeuroPace reports Q4 revenue $21.5M (+19% YoY); guides FY2025 revenue $92-96M

NeuroPace Inc

Q4 2024 revenue $21.5M (+19% YoY); full year revenue $79.9M (+22%).
Net loss improved: Q4 $5.3M (vs $6.2M); full year $27.1M (vs $33.0M).
FY2025 guidance: revenue $92-96M (15-20% growth), gross margin 73-75%, operating expenses $92-95M.
Completed $74.8M public offering; used $49.5M to repurchase 5.3M shares from KCK Ltd.; pro forma cash $68.6M.
NAUTILUS study completes March 2025; FDA submission H2 2025; NEST pediatric program for indication expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.